Chemomab Therapeutics Ltd. CMMB

CMMB Company Overview

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company focused on the development of therapeutics for fibro-inflammatory diseases with high unmet medical need. The company operates within the biotechnology and biopharmaceutical industries, with a primary focus on developing monoclonal antibody therapies targeting the soluble protein CCL24, a chemokine associated with fibrosis and inflammation. Chemomab’s lead product candidate, CM-101, is being evaluated for conditions including primary sclerosing cholangitis (PSC) and systemic sclerosis-associated interstitial lung disease (SSc-ILD), both of which currently have limited treatment options. The company primarily serves healthcare providers, specialty treatment centers, and future commercial markets in rare and chronic inflammatory diseases.

Chemomab was founded in Israel and later established a broader corporate presence through public market activity in the United States. The company became publicly traded on Nasdaq under the ticker CMMB following a business combination involving a special purpose acquisition company. Its strategic positioning is centered on targeting the CCL24 pathway, which the company believes may play a central role in fibrosis and inflammatory signaling across multiple organ systems. Data from clinical and preclinical studies have positioned CM-101 as the company’s primary value driver.